High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy represents the most advanced immunotherapy against relapsed/refractory B cell malignancies. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are distinctive, known CAR T-cell acute adverse events, he...

Descripción completa

Detalles Bibliográficos
Autores principales: Accorsi Buttini, Eugenia, Farina, Mirko, Lorenzi, Luisa, Polverelli, Nicola, Radici, Vera, Morello, Enrico, Colnaghi, Federica, Almici, Camillo, Ferrari, Emilio, Bianchetti, Andrea, Leoni, Alessandro, Re, Federica, Bosio, Katia, Bernardi, Simona, Malagola, Michele, Re, Alessandro, Russo, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897055/
https://www.ncbi.nlm.nih.gov/pubmed/36741006
http://dx.doi.org/10.3389/fonc.2023.1036455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897055/
https://www.ncbi.nlm.nih.gov/pubmed/36741006
http://dx.doi.org/10.3389/fonc.2023.1036455

Ejemplares similares